Human CD152/CTLA4 (JMW-3B3) Antibody is a research-grade biosimilar monoclonal antibody. It is a human IgG antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Cytotoxic T-lymphocyte protein 4 (CD152/CTLA4) is a ~24 kDa protein. Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. CD152 is the therapeutic target of ipilimumab (Yervoy).
Product Name:
Human CD152/CTLA4 (JMW-3B3) Antibody
SKU:
GXBS01230
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Clone:
JMW-3B3
Target:
CD152
Isotype:
IgG
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Synonyms:
JMW-3B3, JMW3B3, JMW3B3
Biological Activity:
Biotinylated JMW-3B3 (10 ug/mL) specifically detects sCTLA-4 in PBMC cell culture supernatants, and reveals no population-level difference in sCTLA-4 production between SLE patient and healthy donor PBMC stimulated with lupus-associated autoantigenic peptides [1]. JMW-3B3 (10 ug/mL; 5 days) blocks sCTLA-4 activity in PBMC from both healthy donors and SLE patients, with effects that vary by stimulant: it suppresses some pro-inflammatory and proliferative responses in healthy donors, while enhancing IL-10 production (and altering proliferation/cytokine profiles) in SLE patient PBMC, accentuating the inherent cytokine response differences between the two groups [1]. JMW-3B3 (20 ug/mL; overnight at 4°C) selectively binds intracellular sCTLA-4 in G-361 human malignant melanoma epithelial cells, but does not detect sCTLA-4 in A-375 human malignant melanoma epithelial cells [2]. JMW-3B3 (10 ug/mL; 5 days) enhances IFN-γ production from melanoma patient PBMC stimulated with a low dose (0.02 ug/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment [2]. JMW-3B3 (10 ug/mL; 5 days) enhances IL-17A production from healthy donor PBMC stimulated with a high dose (1 ug/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment [2].
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
